Prices Increased Faster Than Inflation for Half of all Drugs Covered by Medicare in 2020 February 25, 2022 Issue Brief Recent legislation would require drug companies to pay rebates to the federal government when annual increases in prescription drug prices for Medicare and private insurance exceed the rate of inflation. As context for understanding the possible impact of this proposal, this analysis compares price changes for drugs covered by Medicare Part B (administered by physicians) and Part D (retail prescription drugs) between 2019 and 2020 to the inflation rate over the same period.
People With HIV in Non-Medicaid Expansion States: Who Could Gain Coverage Eligibility Through Build Back Better or Future Expansion? February 15, 2022 Issue Brief In this analysis, we explore the implications of the Build Back Better Act’s current coverage provisions for people with HIV in select non-expansion states. We estimate the size of the population that could gain eligibility as well as their socio-demographic characteristics, examine their affordability barriers and assess the potential impact on the Ryan White HIV/AIDS Program. We also explore what Medicaid expansion could mean in these non-expansion states for people with HIV.
Medicaid Financing and the U.S. Territories: Implications of The Build Back Better Act February 9, 2022 Blog The U.S territories have faced an array of longstanding fiscal and health challenges that were exacerbated by recent natural disasters and the COVID-19 pandemic. This policy watch examines how Medicaid funding for the territories works, the current allotments, and how the Build Back Better Act (BBA) would change Medicaid funding for the territories going forward. While a version of BBBA has passed the house, its fate in the Senate remains uncertain.
Simulating the Impact of the Drug Price Negotiation Proposal in the Build Back Better Act January 27, 2022 Issue Brief The Build Back Better Act (BBBA) includes a range of health and other proposals supported by President Biden, including a proposal to allow the federal government to negotiate the price of some prescription drugs covered under Medicare Part B (administered by physicians) and Medicare Part D (retail outpatient drugs). This brief illustrates the potential scope of the drug price negotiation proposal in the BBBA. This analysis is designed to highlight the types of Medicare-covered drugs that could be subject to negotiation, and which of the current top-spending drugs covered by Part B and Part D could be subject to price negotiation, and in what years, if the BBBA is enacted.
Millions of Medicare Beneficiaries Use Prescription Drugs That Could Be Subject to Price Negotiation, But Build Back Better Act Provision Exempts Many Drugs With High Federal Spending January 27, 2022 News Release Twenty drugs and dozens of insulin products used by 8.5 million Medicare beneficiaries would be subject to government drug price negotiation if the Build Back Better Act (BBBA) were enacted and fully implemented in 2022, according to a new KFF analysis. The 20 drugs include 18 drugs available to beneficiaries…
What to Watch in Medicaid Section 1115 Waivers One Year into the Biden Administration January 27, 2022 Issue Brief Section 1115 demonstration waivers provide states an avenue to test new approaches in Medicaid and generally reflect changing priorities from one presidential administration to another. This issue brief summarizes waiver priorities and actions under the Biden Administration as well as pending waiver themes and other issues to watch. If the Build Back Better Act (BBBA) fails to pass or is narrowed significantly, Medicaid waivers and other administrative actions may be a key tool for the Biden Administration to advance policy priorities absent legislation.
Medicare’s Coverage Decision for the New Alzheimer’s Drug and Why It Matters January 14, 2022 Blog This policy watch discusses the implications of Medicare’s preliminary National Coverage Determination for the new Alzheimer’s drug, Aduhelm, on the 2022 Medicare Part B premium and the possibility of an adjustment based on the coverage decision. The piece also discusses the implications for Medicare spending and the connection to ongoing policy discussions around prescription drug proposals in the Build Back Better Act.
Medicaid: What to Watch in 2022 January 18, 2022 Issue Brief As 2022 kicks off, a number of issues are at play that could affect coverage and financing under Medicaid. This issue brief examines key issues to watch in Medicaid in the year ahead.
Maternal Health in the Build Back Better Act December 16, 2021 Blog This policy watch highlights the different provisions and potential impact on parents and children in America. From expanding Medicaid postpartum coverage to establishing a national paid family leave policy, the BBBA could provide more support to states and community organizations working to improve maternal health.
New KFF Resource Explains Key Provisions for Maternal Health Within the Build Back Better Act December 16, 2021 News Release If passed, the Build Back Better Act (BBBA) would include several provisions to improve maternal health, particularly for people of color. A new KFF Policy Watch explains the different provisions, their potential impact on parents and children, as well as the projected federal costs of these proposals. From expanding Medicaid…